MX2018000696A - Anticuerpos humanizados anti-beta-amiloide piroglutamados. - Google Patents
Anticuerpos humanizados anti-beta-amiloide piroglutamados.Info
- Publication number
- MX2018000696A MX2018000696A MX2018000696A MX2018000696A MX2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A
- Authority
- MX
- Mexico
- Prior art keywords
- humanized antibodies
- amyloidosis
- amyloid beta
- pyroglutamated
- peptide
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 206010002022 amyloidosis Diseases 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000009825 accumulation Methods 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- 230000008021 deposition Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035474 group of disease Diseases 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Abstract
La invención se refiere a anticuerpos humanizados que se unen a un epítopo en N-terminal de péptido beta-amiloide (Aß N3pE) piroglutamado y a tratamiento preventivo y terapéutico de enfermedades y condiciones relacionadas con la acumulación y deposición de péptidos amiloide, tales como amiloidosis, un grupo de trastornos y anormalidades asociados con el péptido amiloide piroglutamado, tal como la enfermedad de Alzheimer, síndrome de Down, angiopatía amiloide cerebral y otros aspectos relacionados. Más específicamente, pertenece al uso de anticuerpos monoclonales humanizados para unirse al péptido beta amiloide piroglutamado en plasma, cerebro y fluido cerebroespinal para prevenir la acumulación o la deposición inversa de Aß N3pE dentro del cerebro y en varios tejidos en la periferia, y para aliviar la amiloidosis. La presente invención además pertenece a ensayos de diagnóstico para el diagnóstico de amiloidosis utilizando los anticuerpos humanizados de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193356P | 2015-07-16 | 2015-07-16 | |
| US201562209650P | 2015-08-25 | 2015-08-25 | |
| PCT/EP2016/066924 WO2017009459A2 (en) | 2015-07-16 | 2016-07-15 | Humanized antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000696A true MX2018000696A (es) | 2018-05-28 |
Family
ID=56411667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000696A MX2018000696A (es) | 2015-07-16 | 2016-07-15 | Anticuerpos humanizados anti-beta-amiloide piroglutamados. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10603367B2 (es) |
| EP (1) | EP3322723A2 (es) |
| JP (2) | JP7002811B2 (es) |
| KR (1) | KR102786380B1 (es) |
| CN (1) | CN108699139B (es) |
| AU (1) | AU2016293104B2 (es) |
| BR (1) | BR112018000097A2 (es) |
| CA (1) | CA2992386A1 (es) |
| EA (1) | EA038120B1 (es) |
| IL (1) | IL256579B2 (es) |
| MX (1) | MX2018000696A (es) |
| NZ (1) | NZ739181A (es) |
| WO (1) | WO2017009459A2 (es) |
| ZA (1) | ZA201800048B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| AU2019354714A1 (en) * | 2018-10-04 | 2021-04-29 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Humanised anti-N-truncated amyloid beta monoclonal antibody |
| JP7617848B2 (ja) | 2019-03-26 | 2025-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ピログルタメートアミロイド－βに対する抗体及びその使用 |
| WO2021005857A1 (ja) * | 2019-07-05 | 2021-01-14 | 株式会社 島津製作所 | アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法 |
| WO2021024209A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Inc. | Antibodies that bind to pathological tau species and uses thereof |
| IL300059A (en) | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-abeta antibodies |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| MX2024005072A (es) * | 2021-10-28 | 2024-09-06 | Abbvie Inc | Anticuerpos anti-amiloide beta y métodos de uso de los mismos. |
| CN115354048B (zh) * | 2022-06-08 | 2024-02-02 | 暨南大学 | 阿尔茨海默病动物模型的构建方法、用途和Aβ42重组表达载体 |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8058405B2 (en) * | 2008-07-21 | 2011-11-15 | Probiodrug (AG) | Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides |
| US20110002945A1 (en) * | 2009-07-01 | 2011-01-06 | O'nuallain Brian | Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins |
| EP2603524A1 (en) * | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| KR102020072B1 (ko) * | 2011-03-16 | 2019-11-04 | 프로비오드룩 아게 | 진단 항체 시험 |
| US9499610B2 (en) * | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
-
2016
- 2016-07-15 IL IL256579A patent/IL256579B2/en unknown
- 2016-07-15 BR BR112018000097A patent/BR112018000097A2/pt active Search and Examination
- 2016-07-15 CA CA2992386A patent/CA2992386A1/en active Pending
- 2016-07-15 KR KR1020187004514A patent/KR102786380B1/ko active Active
- 2016-07-15 MX MX2018000696A patent/MX2018000696A/es unknown
- 2016-07-15 NZ NZ739181A patent/NZ739181A/en unknown
- 2016-07-15 WO PCT/EP2016/066924 patent/WO2017009459A2/en active Application Filing
- 2016-07-15 CN CN201680053883.XA patent/CN108699139B/zh active Active
- 2016-07-15 JP JP2018501891A patent/JP7002811B2/ja active Active
- 2016-07-15 AU AU2016293104A patent/AU2016293104B2/en active Active
- 2016-07-15 EA EA201890313A patent/EA038120B1/ru not_active IP Right Cessation
- 2016-07-15 EP EP16738828.9A patent/EP3322723A2/en active Pending
-
2018
- 2018-01-04 ZA ZA2018/00048A patent/ZA201800048B/en unknown
- 2018-01-10 US US15/866,773 patent/US10603367B2/en active Active
-
2020
- 2020-01-16 US US16/744,404 patent/US11045533B2/en active Active
-
2021
- 2021-10-07 JP JP2021165152A patent/JP2022017271A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11045533B2 (en) | 2021-06-29 |
| KR102786380B1 (ko) | 2025-03-26 |
| IL256579A (en) | 2018-02-28 |
| US20180140689A1 (en) | 2018-05-24 |
| US20200138922A1 (en) | 2020-05-07 |
| IL256579B2 (en) | 2023-03-01 |
| WO2017009459A3 (en) | 2017-03-16 |
| EA038120B1 (ru) | 2021-07-08 |
| AU2016293104B2 (en) | 2022-08-11 |
| CN108699139B (zh) | 2022-06-24 |
| JP2022017271A (ja) | 2022-01-25 |
| IL256579B (en) | 2022-11-01 |
| AU2016293104A1 (en) | 2018-02-08 |
| ZA201800048B (en) | 2018-11-28 |
| EA201890313A1 (ru) | 2018-09-28 |
| WO2017009459A2 (en) | 2017-01-19 |
| JP2018524370A (ja) | 2018-08-30 |
| CN108699139A (zh) | 2018-10-23 |
| BR112018000097A2 (pt) | 2018-09-04 |
| CA2992386A1 (en) | 2017-01-19 |
| NZ739181A (en) | 2023-05-26 |
| JP7002811B2 (ja) | 2022-03-04 |
| US10603367B2 (en) | 2020-03-31 |
| EP3322723A2 (en) | 2018-05-23 |
| KR20180030653A (ko) | 2018-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000696A (es) | Anticuerpos humanizados anti-beta-amiloide piroglutamados. | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| WO2017184619A3 (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| WO2019098763A3 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MY164579A (en) | Safe and functional humanized antibodies | |
| PH12015500767A1 (en) | Antibodies recognizing alpha-synuclein | |
| GT201100283A (es) | Anticuerpos humanizados especificos de la forma protofibrilar del péptido beta-amiloide | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| PH12015500507A1 (en) | Humanized antibodies to amyloid beta | |
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| WO2016005466A3 (en) | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES | |
| EP2650308A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| DOP2017000071A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. | |
| MX2020007986A (es) | Anticuerpos humanizados y desinmunizados. | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| WO2017049038A3 (en) | Anti-cd115 antibodies | |
| WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| PH12014502582A1 (en) | Compounds | |
| PH12012501882A1 (en) | Humanized antibody against amyloid beta | |
| WO2016150415A8 (de) | Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz | |
| EA201991020A3 (ru) | Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений |